相关实验视频
Updated: Jul 20, 2026

08:52
Evaluation of Host-Pathogen Responses and Vaccine Efficacy in Mice
Published on: February 22, 2019
10.7K
瑞-生物科技 (BNT162b2) 疫苗在青少年 (12-15岁) 中的有效性:卡塔尔的一项观察性研究
Maktoum Abdul Azeez1,2,3,4, Mir Saad Hussain5, Shajitha Thekke Veettil6
1Al Waab Health Center, Primary Health Care Corporation, Doha, Qatar.
Clinical pediatrics
|November 22, 2023
概括
瑞-生物科技的COVID-19疫苗对卡塔尔12-15岁的青少年提供了良好的保护. 增剂剂量可能进一步增强对SARS-CoV-2的保护.
科学领域:
- * * 公共卫生 公共卫生
- * 疫苗学 疫苗学 疫苗学
- * 青少年医学 青少年医学
背景情况:
- *卡塔尔于2021年5月启动了针对青少年 (12-15岁) 的BNT162b2 (Pfizer-BioNTech) COVID-19疫苗接种活动.
- *在这个人口群体中评估疫苗的安全性和有效性对于公共卫生战略至关重要.
研究的目的:
- *评估瑞-生物科技公司在卡塔尔青少年中的COVID-19疫苗的安全性和有效性.
- *为了比较疫苗接种和未接种青少年之间的SARS-CoV-2感染率.
主要方法:
- * 追溯观察性研究设计.
- *对1956名青少年 (12-15岁) 的医疗记录进行分析,这些青少年在2021年6月17日至12月17日期间检测出SARS-CoV-2阳性.
- * 接种疫苗和未接种疫苗群体之间的人口统计数据比较.
主要成果:
- * Pfizer-BioNTech疫苗证明了令人满意的保护,仅有20%的接种疫苗的研究人口在双剂量治疗后感染了SARS-CoV-2.
- *参与者的平均年龄为疫苗接种组的13.89 ± 0.93岁,未接种组的12.99 ± 0.93岁.
- *人口分布显示在接种疫苗和未接种疫苗的群体之间存在轻微的性别差异.
结论:
- *BNT162b2疫苗对青少年的SARS-CoV-2感染提供了显著的保护.
- * 建议最大限度地提高疫苗接种覆盖率,并考虑再接种剂量,以加强青少年的保护.
- *需要进一步研究长期的安全性和疗效.
更多相关视频
相关概念视频
Vaccinations
Overview
Bioavailability Study Design: Healthy Subjects Versus Patients
Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
Bioequivalence studies: Biowaivers
In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
Pharmacokinetics in Pediatric Patients: Drug Distribution
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Pharmacokinetics in Pediatric Patients: Drug Metabolism
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacokinetics in Pediatric Patients: Drug Excretion
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...

